Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation
CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.
Source: forbes.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Timothy Babich. Real-time updates on events, politics, business and more.